Current track



Current show

The Quiet Storm

22:00 24:00

Single-shot COVID vaccine from Johnson & Johnson up to 85% effective

Written by on 29/01/2021

A single-shot vaccine developed by the healthcare giant Johnson & Johnson is 85% effective in preventing the most serious coronavirus symptoms, according to data from mass trials.

The company said its latest tests – carried out in several countries – also showed it was 66% effective overall at preventing moderate to severe COVID-19, 28 days after vaccination.

It comes as another coronavirus vaccine from Novavax could get the all-clear from UK regulators.

Live COVID updates from the UK and around the world

Please use Chrome browser for a more accessible video player

EU pressures AstraZeneca over shortfall

If approved, the Novavax jab, which trials suggest is 89% effective in preventing the virus, would start to be rolled out in the second half of 2021.

It would follow the Oxford/AstraZeneca, Pfizer/BioNTech and Moderna shots.

However, unlike other COVID-19 jabs, which require two doses several weeks apart, J&J’s is administered in one injection.

More from Covid-19

As well as being one shot, it also only needs to be kept at fridge temperature, making its storage, distribution and handling much easier.

And costing as little as $10 (£7) a dose, it is cheaper than most of the other coronavirus vaccines – coming in at about the same as two shots of the Oxford/AstraZeneca option.

The interim data for the J&J jab will be submitted to regulators and trials will continue – with information being fed back as part of a rolling review.

The injection also worked across multiple variants of coronavirus, including the South African variant which has been worrying scientists, the firm said.

The UK has ordered 30 million doses of the vaccine, pending approval by the Medicines and Healthcare products Regulatory Agency (MHRA), with the option of millions more.

Subscribe to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Meanwhile, the EU regulators are expected to grant restricted approval for the Oxford/AstraZeneca vaccine, which has been the focus of an increasingly bitter dispute in Brussels over supplies.

EU chief Ursula von der Leyen has insisted a contract between Brussels and AstraZeneca contained binding orders.

The contract between the EU and the pharmaceutical firm was published by the bloc on Friday, amid the escalating war of words.

 Sky News

© Sky News 2020

Tagged as